Selected Gilead- initiated - PowerPoint Presentation

1. Selected Gilead-initiated or Gilead-supported Abstracts Published at AIDS 2020Abstracts selected by Gilead Medical Affairs Germany, July 3rd1

2. Selected Gilead-initiated/supported abstractsB/F/TAFTitleSpeakerLink to PresentationLink to SessionPooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older demonstrating safety and efficacy: Week 48 resultsMoti RamgopalOral OAB0403OA-B-04 Antiretrovirals session 2The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH)Olivier RobineauPoster PEB0229E-posters Track BPrevalence and risk factors of pre-existing NNRTI resistance among suppressed PLWH in B/F/TAF switch studiesKristen AndreattaPoster PEB0254E-posters Track BBaseline NRTI resistance in suppressed participants did not lead to viral blips on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+F/TAF through week 48 in study 380-4030Rima AcostaPoster PEB0257E-posters Track BVirtual AIDS 2020, 6 - 10 July 20202Links behind abstract number in column „Link to Presentation“ guide you to the on-demand presentation – just click on the abstract numberLinks in column „Link to Session“ guide you to the online program – just click on the session numberNot all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed

3. Selected Gilead-initiated/supported abstractsVirtual AIDS 2020, 6 - 10 July 20203HIV Cure Agent Vesatolimod (VES, formerly GS-9620)TitleSpeakerLink to PresentationLink to SessionVesatolimod, a toll-like receptor 7 (TLR7) agonist, induces dose-dependent immune responses in HIV controllersJeffrey WallinOral OAB0205OA-B-02 ARV, cure and testing strategiesCapsid Inhibitor Lenacapavir (LEN, formerly GS-6207)TitleSpeakerLink to PresentationLink to SessionGS-6207 sustained delivery formulation supports 6-month dosing intervalRebecca BegleyPoster PEB0265E-posters Track BE/C/F/TAFTitleSpeakerLink to PresentationLink to SessionSafety, pharmacokinetics and efficacy of low-dose E/C/F/TAF in virologically suppressed children ≥ 2 years old living with HIVEva NatukundaLate Breaker Oral OABLB0101Thu, July 92:00 PM (GMT-7)OA-B-LB-01 Track B late-breaker abstractsLinks behind abstract number in column „Link to Presentation“ guide you to the on-demand presentation – just click on the abstract numberLinks in column „Link to Session“ guide you to the online program – just click on the session numberNot all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed

4. Selected Gilead-initiated/supported abstractsF/TAF for PrEPTitleSpeakerLink to PresentationLink to SessionPersistently high rates of sexually transmitted infections in the DISCOVER HIV PrEP trialLinda GorgosPoster Discussion PDB0303PD-B-03 Opportunistic infectionsDeep sequencing with unique molecular identifiers for evaluation of HIV-1 drug resistance in the DISCOVER pre-exposure prophylaxis trialStephanie CoxPoster Discussion PDB0404PD-B-04 ResistanceDiscover study for HIV Pre-Exposure Prophylaxis (PrEP): No evidence of risk compensation in participants taking F/TDF or F/TAF for PrEP through 96 weeksPeter ShalitPoster PEB0165E-posters Track BVirtual AIDS 2020, 6 - 10 July 20204Links behind abstract number in column „Link to Presentation“ guide you to the on-demand presentation – just click on the abstract numberLinks in column „Link to Session“ guide you to the online program – just click on the session numberNot all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed

5. 5HIV Treatment Including ComorbiditiesTitleSpeakerLink to PresentationLink to SessionReducing ART to less than 3-ARV regimen linked to increased systemic inflammationSergio Serrano-VillarOral OAB0304OA-B-03 Antiretrovirals session 1Modelling endothelial function in vitro and via blood sampling to assess cardiovascular risk in people living with HIVAkif A. KhawajaPoster Discussion PDA0105PD-A-01 HIV, co-infection and co-morbiditiesPatterns of antiretroviral use and immunologic correlates in the REPRIEVE trial at study entryCarl J FichtenbaumPoster PEB0181E-posters Track BHIV and comorbidities: The impact of comorbidities on health-related quality of life in people living with HIV in ItalyLucrezia Ferrario,Poster PED0833E-posters Track DSelected Gilead-initiated/supported abstractsVirtual AIDS 2020, 6 - 10 July 2020Links behind abstract number in column „Link to Presentation“ guide you to the on-demand presentation – just click on the abstract numberLinks in column „Link to Session“ guide you to the online program – just click on the session numberNot all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed

6. 6HIV Treatment Including ComorbiditiesTitleSpeakerLink to PresentationLink to SessionThird-line antiretroviral therapy including raltegravir, darunavir/ritonavir and/or etravirine is well tolerated and achieves durable virologic suppression over 144+ weeks in resource limited settings ACTG: A5288 strategy trialAnchalee AvihingsanonOral OAB0404OA-B-04 Antiretrovirals session 2POP-UP clinic: A multicomponent model of care for people living with HIV (PLHIV) who experience homelessness or unstable housing (HUH)Elizabeth ImbertOral OAE0406OA-E-04Innovation in initiation, treatment and care: Differentiated Service DeliveryHair concentration of antiretroviral drugs, but not self-reported adherence, is associated with ongoing virologic failure among individuals in Resource Limited Settings (RLS) on second line Antiretroviral Therapy (ART)Tanakorn ApornpongPoster PEB0245E-posters Track BSelected Gilead-initiated/supported abstractsVirtual AIDS 2020, 6 - 10 July 2020Links behind abstract number in column „Link to Presentation“ guide you to the on-demand presentation – just click on the abstract numberLinks in column „Link to Session“ guide you to the online program – just click on the session numberNot all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed

7. 7HIV Treatment Including ComorbiditiesTitleSpeakerLink to PresentationLink to SessionChanges in body mass index over time in persons with and without HIVMichael SilverbergOral OAB0603OA-B-06 Weight and metabolic changes & ARTThe predicted risk of adverse pregnancy outcomes from treatment-induced obesity in the ADVANCE trialSumbul Fatima AsifLate Breaker Oral OABLB0103Thu, July 92:00 PM (GMT-7)OA-B-LB-01 Track B late-breaker abstractsThe ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infectionSimiso SokhelaLate Breaker Oral OAXLB0104Wed, July 82:01 PM (GMT-7)OA-X-LB-01 Co-Chairs' ChoiceSelected Gilead-initiated/supported abstractsVirtual AIDS 2020, 6 - 10 July 2020Links behind abstract number in column „Link to Presentation“ guide you to the on-demand presentation – just click on the abstract numberLinks in column „Link to Session“ guide you to the online program – just click on the session numberNot all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed

8. Selected Gilead-initiated/supported abstractsVirtual AIDS 2020, 6 - 10 July 20208Testing, Test and Treat, Rapid StartTitleSpeakerLink to PresentationLink to SessionGeographic hotspots of high population HIV viremia and association with HIV incidence in a universal test-and-treat setting in rural Uganda and KenyaJames PengOral OAC0203OA-C-02 Can we achieve UTT? What can UTT achieve?Evaluation of an emergency department-based opt-out HIV screening program in South FloridaPaula A EckardtPoster PEB0107 E-posters Track BPrevalence of HIV and other sexually transmitted infections among young Thai men and transgender women selling or trading sex in the COPE4YMSM studyAndrew HickeyPoster PEC0409E-posters Track CThe UCSF Acute HIV Cohort: High virologic suppression and long-term retention rates in a contemporary San Francisco Bay Area cohort of acute HIV-infected individuals receiving immediate ART at diagnosisSulggi LeePoster PEC0483E-posters Track CCharacterizing new HIV infections within SEARCH, a universal test and treat trial in rural East AfricaMarilyn NyabutiPoster PEC0708E-posters Track C"Why start later if I can start today?" Patient perspectives on the experience of rapid/same-day linkage and antiretroviral therapy after HIV diagnosisKaterina A. ChristopoulosPoster PED0809E-posters Track DLinks behind abstract number in column „Link to Presentation“ guide you to the on-demand presentation – just click on the abstract numberLinks in column „Link to Session“ guide you to the online program – just click on the session numberNot all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed

9. 9Prevention including PrEPTitleSpeakerLink to PresentationLink to SessionLower than expected HIV incidence among men and women at elevated HIV risk in a population-based PrEP study in rural Kenya and Uganda: Interim results from the SEARCH studyCatherine KossOral OAC0805OA-C-08 PrEP at ScaleHPTN 083 interim results: Efficacy of pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is maintained across regions and key populationsBeatriz GrinsztejnLate Breaker Oral OACLB0101Thu, July 91:01 AM (GMT-7)OA-C-LB-01 Track C late-breaker abstractsImpact of COVID-19 related shelter-in-place orders on PrEP access, usage and HIV risk behaviors in the United StatesScott BrawleyLate Breaker Oral OADLB0101Wed, July 81:01 AM (GMT-7)OA-D-LB-01 Track D late-breaker abstractsHPTN083 interim results: Pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM,TGW)Raphael LandovitzLate Breaker Oral OAXLB0101Wed, July 82:01 PM (GMT-7)OA-X-LB-01 Co-Chairs' ChoiceSelected Gilead-initiated/supported abstractsVirtual AIDS 2020, 6 - 10 July 2020Links behind abstract number in column „Link to Presentation“ guide you to the on-demand presentation – just click on the abstract numberLinks in column „Link to Session“ guide you to the online program – just click on the session numberNot all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed

10. 10Prevention including PrEPTitleSpeakerLink to PresentationLink to SessionFood insecurity highly prevalent and associated with early PrEP non-adherence among trans and non-binary people in the San Francisco Bay Area: The STAY StudyAlbert LiuPoster Discussion PDC0203PD-C-02 Gaps in our response: Who are we missing?Preventing HIV and achieving pregnancy among HIV-discordant couples using safer conception strategies in ZimbabweJoelle BrownPoster Discussion PDC0402PD-C-04 Untangling the web of sexual reproductive health and sex differences in preventionHigh risk pregnant women initiation and persist on PrEP in Cape Town, South African cohortDvora Joseph DaveyLate Breaker Poster LBPEC24Track C late-breaker posters "Even if you get raped you are protected": Results from a mixed-methods, multi-site study of PrEP engagement among transgender women in South AfricaTonia PoteatPoster PEC0405E-posters Track CFactors affecting PrEP uptake and time to initiation among transgender participants in the TRIUMPH PrEP demonstration project in Oakland and Sacramento, CaliforniaJae SeveliusPoster PEC0595E-posters Track CSelected Gilead-initiated/supported abstractsVirtual AIDS 2020, 6 - 10 July 2020Links behind abstract number in column „Link to Presentation“ guide you to the on-demand presentation – just click on the abstract numberLinks in column „Link to Session“ guide you to the online program – just click on the session numberNot all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed

11. 11Prevention including PrEPTitleSpeakerLink to PresentationLink to SessionPre-exposure prophylaxis among Brazilian transwomen: Retention and adherence in 48 weeks follow-up of PrEParadas studyEmilia JalilPoster PEC0604E-posters Track C Long-term patterns of PrEP adherence and association with HIV seroconversion in a large-scale implementation study in New South Wales (EPIC-NSW), AustraliaFengyi JinPoster PEC0627E-posters Track CUptake and outcomes of a novel community-based post-exposure prophylaxis (PEP) program in rural Kenya and UgandaJames AyiekoPoster PEC0655E-posters Track CUtility of PSA to assess self-reported protected sex among HIV discordant couplesAllen MatubuPoster PEC0658E-posters Track CExpanding the reach of pre-exposure prophylaxis to trans and non-binary communities in the San Francisco Bay Area: Development and evaluation of the STAY Study PrEP CampaignErin C. WilsonPoster PEC0676E-posters Track CFeasibility and acceptability of HIV prevention research among young transgender women who sell or trade sex in Bangkok and Pattaya, ThailandTareerat ChemnasiriPoster PED1105E-posters Track DSelected Gilead-initiated/supported abstractsVirtual AIDS 2020, 6 - 10 July 2020Links behind abstract number in column „Link to Presentation“ guide you to the on-demand presentation – just click on the abstract numberLinks in column „Link to Session“ guide you to the online program – just click on the session numberNot all Internet Browser seem to work, please test different Internet Browsers in case content is not displayed

12. Selected Gilead-initiated or Gilead-supported Abstracts Published at COVID-19 ConferenceAbstracts selected by Gilead Medical Affairs Germany, July 3rd12

13. Selected Gilead-initiated/supported abstractsCOVID-19 / RemdesivirTitleSpeakerAbstractLink to SessionBaseline characteristics associated with clinical improvement and mortality in hospitalized patients with severe COVID-19 treated with RemdesivirKristen MarksOralFri, July 1011:00 AM (GMT-7)Track B:Clinical science,testing (RT-PCR and serologic) and diagnoses, natural history, clinical care, ARDS care, therapeuticsRemdesivir for severe COVID-19 versus a cohort receiving standard of careSusan OlenderPosterCompassionate use of remdesivir in children with severe COVID-19Kathleen ChiotosPosterCompassionate use of remdesivir in pregnant women with severe COVID-19Richard BurwickPosterAssociation between concomitant hydroxychloroquine use and safety and efficacy of remdesivir in severe COVID-19 patientsGeorge DiazPosterExposure to remdesivir through compassionate use: Safety and efficacy in 163 patientsRenato MaseratiPosterRacial/ethnic disparities not observed in clinical outcomes with remdesivir treatmentKathleen MullanePosterVirtual COVID-19 Conference, 10 – 11 July 202013